DK0824358T3 - Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf - Google Patents

Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf

Info

Publication number
DK0824358T3
DK0824358T3 DK96911886T DK96911886T DK0824358T3 DK 0824358 T3 DK0824358 T3 DK 0824358T3 DK 96911886 T DK96911886 T DK 96911886T DK 96911886 T DK96911886 T DK 96911886T DK 0824358 T3 DK0824358 T3 DK 0824358T3
Authority
DK
Denmark
Prior art keywords
pref
iii
pertussis
toxoid
agg
Prior art date
Application number
DK96911886T
Other languages
Danish (da)
English (en)
Inventor
Michel H Klein
Raafat E F Fahim
John R Vose
Gail E D Jackson
Larry U L Tan
Andrew Herbert
Leslie Boux
Luis Barreto
John Thipphawong
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of DK0824358T3 publication Critical patent/DK0824358T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/099Bordetella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96911886T 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf DK0824358T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12
PCT/CA1996/000278 WO1996034623A1 (en) 1995-05-04 1996-05-02 Acellular pertussis vaccines and methods of preparation thereof

Publications (1)

Publication Number Publication Date
DK0824358T3 true DK0824358T3 (da) 2003-01-27

Family

ID=27029924

Family Applications (3)

Application Number Title Priority Date Filing Date
DK03078355.9T DK1393744T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf
DK96911887T DK0826001T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf
DK96911886T DK0824358T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling deraf

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK03078355.9T DK1393744T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf
DK96911887T DK0826001T3 (da) 1995-05-04 1996-05-02 Acellulære pertussisvacciner og fremgangsmåder til fremstilling heraf

Country Status (18)

Country Link
US (1) US6399076B2 (zh)
EP (7) EP1234579A1 (zh)
CN (2) CN100387618C (zh)
AT (3) ATE496634T1 (zh)
AU (2) AU715417B2 (zh)
BR (2) BR9608114A (zh)
CA (3) CA2220048C (zh)
DE (3) DE69625191T2 (zh)
DK (3) DK1393744T3 (zh)
ES (2) ES2182971T3 (zh)
FR (1) FR16C0015I2 (zh)
HK (1) HK1016191A1 (zh)
LU (1) LU93036I2 (zh)
MX (1) MX9708481A (zh)
NL (1) NL300804I2 (zh)
NZ (2) NZ306391A (zh)
PT (3) PT826001E (zh)
WO (2) WO1996034883A1 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
ATE183194T1 (de) * 1994-04-28 1999-08-15 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
EP1123711B9 (en) * 1998-10-21 2009-08-12 The Kitasato Institute Attenuated toxins as adjuvants
KR101320905B1 (ko) * 2003-11-20 2013-11-06 사노피 파스퇴르 인크 백일해 독소의 정제방법 및 이에 유용한 펩타이드
DK1828378T3 (da) * 2004-12-17 2014-09-01 Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheit Welzijn En Sport Deacylering af LPS i gram-negative bakterier
PL1942932T3 (pl) 2005-08-08 2013-11-29 Univ Oregon Health & Science Inaktywacja patogenów nadtlenkiem wodoru do wytwarzania szczepionek
EP1867638A1 (de) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
WO2008028957A2 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Vaccine
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
EP2430040A1 (en) 2009-05-11 2012-03-21 Novartis AG Antigen purification process for pertactin antigen
EP2758429A4 (en) * 2011-09-20 2015-09-02 Bio Rad Laboratories REMOVAL OF VIRUS DUSTING SUBSTANCES FROM BIOMOLECULAR PREPARATIONS
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
US8916173B2 (en) * 2013-03-08 2014-12-23 Crucell Holland B.V. Acellular pertussis vaccine
CN107921407B (zh) 2015-06-05 2022-07-05 格雷斯公司 生物处理吸附澄清剂及其制备和使用方法
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
EP4070815A1 (en) 2016-10-03 2022-10-12 The U.S.A. as represented by the Secretary, Department of Health and Human Services Hiv-1 env fusion peptide immunogens and their use
US11202824B2 (en) 2016-10-31 2021-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
EP3600405A1 (en) 2017-03-24 2020-02-05 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of hiv-1 gp120 and their use
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
WO2020061564A1 (en) 2018-09-23 2020-03-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
US20210340188A1 (en) 2018-10-22 2021-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Recombinant gp120 protein with v1-loop deletion
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
AU2022323509A1 (en) 2021-08-03 2024-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
KR0168039B1 (ko) * 1987-09-04 1999-01-15 로버트 디. 웨스트 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
WO1990012086A1 (en) * 1989-03-31 1990-10-18 Washington University Bordetella vaccines
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ATE183194T1 (de) * 1994-04-28 1999-08-15 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
AU715417B2 (en) 2000-02-03
LU93036I2 (fr) 2016-06-21
US20010009666A1 (en) 2001-07-26
EP1233022A1 (en) 2002-08-21
NZ306391A (en) 1999-03-29
HK1016191A1 (en) 1999-10-29
ATE496634T1 (de) 2011-02-15
DE69622555D1 (de) 2002-08-29
ES2180758T3 (es) 2003-02-16
EP1405643A1 (en) 2004-04-07
EP1234579A1 (en) 2002-08-28
PT1393744E (pt) 2011-05-03
CN1198099A (zh) 1998-11-04
DK1393744T3 (da) 2011-05-30
CA2220048C (en) 2006-03-07
NZ306392A (en) 1999-04-29
MX9708481A (es) 1998-02-28
CA2433502A1 (en) 1996-11-07
BR9608115A (pt) 2004-07-13
EP1234580A1 (en) 2002-08-28
PT826001E (pt) 2002-12-31
ES2182971T3 (es) 2003-03-16
EP1393744B1 (en) 2011-01-26
CA2220063A1 (en) 1996-11-07
CN1193324A (zh) 1998-09-16
CA2220063C (en) 2003-08-26
AU5494096A (en) 1996-11-21
NL300804I2 (zh) 2016-11-01
CA2220048A1 (en) 1996-11-07
CN100387618C (zh) 2008-05-14
EP0826001A1 (en) 1998-03-04
FR16C0015I2 (fr) 2017-06-09
US6399076B2 (en) 2002-06-04
DE69625191D1 (de) 2003-01-16
EP0824358A1 (en) 1998-02-25
DK0826001T3 (da) 2002-11-18
AU5494196A (en) 1996-11-21
WO1996034623A1 (en) 1996-11-07
EP1393744A1 (en) 2004-03-03
EP1233022B1 (en) 2015-12-09
FR16C0015I1 (zh) 2016-06-10
DE69638326D1 (de) 2011-03-10
PT824358E (pt) 2003-02-28
BR9608114A (pt) 2000-10-31
DE69625191T2 (de) 2003-07-10
AU710538B2 (en) 1999-09-23
DE69622555T2 (de) 2003-03-27
ATE221081T1 (de) 2002-08-15
ATE228851T1 (de) 2002-12-15
WO1996034883A1 (en) 1996-11-07
EP0824358B1 (en) 2002-12-04
EP0826001B1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
FR16C0015I2 (fr) Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants
AU4267093A (en) Vaccine compositions for mucosal delivery
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
LU91155I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutininine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type 1, type 2 et type 3.
CA2271008A1 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
EP0761230A3 (en) Vaccine containing Bordetella pertussis outer membrane protein, and method of making such vaccine
CA2427475A1 (en) Purification of hbv antigens for use in vaccines
WO1997045139A3 (en) Il-12 as an adjuvant for bordetella pertussis vaccines
DK0833903T3 (da) Multivalent vaccine mod bovint coronavirus og fremgangsmåde til behandling af infektioner forårsaget af bovint coronavirus
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
US8623380B2 (en) Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
MXPA99004278A (es) Vacuna de pertusis acelular con toxoides de difteria y tetanos
SA96170157B1 (ar) تركيب لقاح composition vaccine يشتمل على مولد مضاد متعدد سكريد مقترن antigen conjugated polsaccharide يتم امتزازه على فوسفات الألومنيوم aluminum phosphate